Clinical nuance is one of the core tenets of value-based insurance design, which is one possible solution to alleviate the financial burden Americans face as they are asked to pay a greater percentage of their healthcare expenditures.
This article was collaboratively written by A. Mark Fendrick, MD, director of the V-BID Center, and several V-BID Center staff.
As Americans are asked to pay a greater percentage of their healthcare expenditures, cost-related nonadherence is an important and growing problem. A potential solution—Value-Based Insurance Design (VBID)—is built on the principle of lowering or removing financial barriers to essential, high-value clinical services and providers. VBID plans align patients’ out-of-pocket costs, such as copayments, with the value of services.
Clinical nuance is one of the core tenets of VBID. This concept recognizes 2 important facts about the provision of medical care: 1) medical services differ in the amount of health produced; and 2) the clinical benefit derived from a medical service depends on who is using it, who is delivering the service, and where it is being delivered.
To learn more about clinical nuance, view the video below, and visit
.
the Clinical Nuance initiative page
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More